BioSpace News Archive

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported preliminary revenue results for its fourth quarter and fiscal year ended December 31, 2019.

Commercial Preparations on Track for Potential 2020 EU Launch of OTL-200 for Metachromatic Leukodystrophy (MLD) with U.S. Regulatory Filing Expected Late 2020 / Early 2021

Aeglea BioTherapeutics, Inc. announced it has filed a Clinical Trial Application with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for ACN00177, a novel engineered human enzyme therapy designed to treat homocystinuria, a serious metabolic disorder that results in elevated levels of plasma homocysteine.

Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors andCYC065-venetoclax combination in AML/MDS and CLL dose escalation studies

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, is presenting at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 5:00 pm Pacific Time where Christian Itin, the chairman and chief executive officer of Autolus, will provide an outlook for 2020.

Sientra, Inc., a medical aesthetics company, announced preliminary unaudited net sales for the fourth quarter 2019.

Safety cohort in the investigator sponsored multiple myeloma study, receiving both carfilzomib and Opdivo®, is now complete and pelareorep will be added to the combination in the next cohort in the coming weeks

Oncologie receives exclusive global license to develop and commercialize navicixizumab

Hensel Phelps, SmithGroup and AVRP Studios Complete $244 Million Expansion That Adds Private Patient Rooms, State-of-the-Art Operating Rooms, and More to South Bay’s Largest Hospital

The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials [13-January-2020] REHOVOT, Israel , Jan. 14, 2020 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), anno